Does BPC 157 Cause Cancer?

Your body is constantly running a repair system, and BPC-157 taps directly into that system to accelerate healing. The problem is that tumors tap into the exact same system to grow. So when people ask whether BPC-157 could feed a cancer they don't know they have, that is not a paranoid question. It is a mechanistically reasonable one.

To understand why, you need to understand how blood vessel growth works in the first place.

Every tissue in your body needs blood supply to survive, and when tissue gets damaged, your body sends out chemical signals that tell nearby blood vessels to branch out and grow toward the injury. This process is called angiogenesis, which is the formation of new blood vessels from existing ones. The key signal in this system is something called VEGF, or vascular endothelial growth factor, which is essentially a chemical distress flare that says "grow blood vessels here." And the cells that respond to that flare do so through receptors on their surface called VEGFR2, which is the main receptor that picks up the VEGF signal and tells the cell to start building.

BPC-157 works by increasing the number of those VEGFR2 receptors on your cells and making the entire pathway more sensitive. A 2017 study in the Journal of Molecular Medicine showed this in a rat hind limb ischemia model, where the tissue was essentially being starved of blood flow, and BPC-157 increased VEGFR2 expression, activated the downstream signaling chain through something called the Akt-eNOS pathway, and produced measurably higher vessel density in the damaged tissue. That is the mechanism behind its reputation for accelerating healing. More receptors means stronger signal means more blood vessels means faster recovery.

Now here is where the concern comes in.

Tumors use this exact pathway. When a tumor reaches roughly 1 to 2 millimeters in size, it can no longer get enough oxygen and nutrients by diffusion alone, so it starts secreting VEGF to recruit its own blood supply. This is called the angiogenic switch, and it is one of the defining moments in tumor progression because once a tumor has its own vasculature, it can grow rapidly and eventually shed cells into the bloodstream. This is actually why an entire class of cancer drugs works by blocking VEGF signaling. Drugs like bevacizumab cut off that recruitment signal, and without a blood supply, the tumor stalls. So if BPC-157 is amplifying the same pathway those drugs are trying to suppress, the theoretical concern writes itself.

There is also a second mechanism worth naming. BPC-157 activates something called FAK-paxillin signaling, which is a pathway involved in how cells anchor to surfaces and migrate through tissue. In the context of healing, that is useful because it helps cells move into a wound. In the context of cancer, FAK-paxillin signaling is one of the known drivers of cancer cell invasion, meaning the process by which tumor cells spread into surrounding tissue. This does not prove that BPC-157 promotes invasion, but it means the same molecular machinery is being engaged.

So what does the actual evidence say?

There is one study that directly tested BPC-157 against cancer cells. A 2004 conference abstract from researchers affiliated with Sikiric, who is the primary investigator behind most BPC-157 research, tested the compound on a human melanoma cell line called SK-Mel-1. At concentrations of 2 nanograms and 10 nanograms, BPC-157 reduced the fraction of cells actively dividing by up to 55% compared to controls. That is a meaningful number if it holds up. The mechanism proposed was inhibition of the MAPK pathway, which is a growth and survival signaling route that many cancers depend on.

But that study has never been independently replicated in over 20 years, and it was a conference abstract, not a full peer-reviewed paper. It was conducted in a single cell line, in a dish, with no immune system, no tumor microenvironment, and no competing tissue to interact with. A 2025 published commentary in Pharmaceuticals reviewed the full landscape of available data and concluded plainly that no published in vivo data demonstrate that BPC-157 inhibits tumor progression, reduces tumor volume, or suppresses metastasis in any living organism.

That is the gap. One unreplicated in vitro result showing possible anti-tumor effects, against a mechanistically coherent concern that the compound could do the opposite, with zero animal or human tumor data either way.

This is not a situation where the evidence leans one direction and we are waiting for confirmation. This is a situation where the question has not been tested at the level needed to answer it, and the 2025 narrative review in Current Reviews in Musculoskeletal Medicine stated the same conclusion directly: BPC-157 should be considered investigational until well-designed human trials are conducted and published.

What this means practically depends on your situation.

If you have no history of cancer and no known high-risk conditions, the theoretical risk from the available data appears low, but that assessment is made in the absence of direct evidence, not because of it. If you have active cancer, a history of cancer, or known precancerous conditions, there is no data that clears BPC-157 as safe for you, and the mechanistic concern is specific enough that avoidance is the only rational position until better data exists.

The deeper point here is about how we reason about theoretical risk. The body does not have a separate healing system and a separate tumor-feeding system. It has one vascular signaling system that serves both purposes depending on context. Any compound that amplifies that system is borrowing against an uncertainty we have not yet measured, and the honest answer is that nobody has measured it yet.

---

References

1. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323-333. Study conditions: Rat hind limb ischemia model and human umbilical vein endothelial cell cultures. Did not test tumor models. Finding: BPC-157 increased VEGFR2 expression and activated the VEGFR2-Akt-eNOS signaling pathway, increasing vessel density in ischemic tissue.
2. Radeljak S, Seiwerth S, et al. BPC 157 inhibits cell growth and VEGF signalling via the MAPK kinase pathway in the human melanoma cell line. Melanoma Research. 2004;14(4):A14-A15 (conference abstract). Study conditions: In vitro, SK-Mel-1 human melanoma cells at 2ng and 10ng concentrations. Authored by Sikiric-affiliated researchers. Never independently replicated. Finding: BPC-157 lowered total S-phase fraction (cell division) up to 55% in SK-Mel-1 melanoma cells compared to controls.
3. Jozwiak M, Bauer M, Kamysz W, Kleczkowska P. Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions. Pharmaceuticals (Basel). 2025;18(10):1451. Published commentary (not original research). Finding: No published in vivo data demonstrate that BPC-157 inhibits tumor progression, reduces tumor volume, or suppresses metastasis. The Radeljak 2004 study remains unreplicated. BPC-157 activates FAK-paxillin signaling, a known pathway in cancer cell invasion.
4. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025;18(12):611-619. Finding: BPC-157 should be considered investigational until well-designed human trials are conducted and published.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness